PROCEPT BioRobotics reports OPEN WATER was a prospective, multicenter, single-arm, open-label clinical trial of the Aquablation procedure.
PROCEPT BioRobotics Announces Three-Year Follow-Up Data Confirming Sustained Efficacy, Superior Safety of Aquablation® Therapy for Benign Prostatic Hyperplasia
The three-year follow-up data from the blinded, randomized WATER clinical study (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) has confirmed the efficacy, safety, and durability of Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH). The data, published in the Canadian Journal of Urology, compared Aquablation therapy, delivered by the AquaBeam® Robotic System, with transurethral resection of the prostate (TURP). This publication not only builds upon the increasing evidence for Aquablation therapy, but also confirms that Aquablation therapy provides both durable symptom relief and a sustained safety advantage compared to TURP.
New Clinical and Real-World Data Highlighting Effectiveness, Durability, Superior Safety and Reproducibility of Aquablation® Therapy for BPH
The company reports new clinical data confirms that PROCEPT BioRobotics’ Aquablation therapy is a durable, safe, effective and reproducible minimally invasive surgical treatment option for benign prostatic hyperplasia
Six-Month Data Highlight Safety and Efficacy of PROCEPT BioRobotics’ Aquablation® Therapy as an Effective Minimally Invasive Surgical Treatment for BPH in Prostates up to 150 mL
3/12/19: Six-month data from the Francais WATER Study (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) evaluating the safety and efficacy of Aquablation therapy at three centers in France will be presented in an expert guided poster tour by Vincent Misrai, M.D., a urologic surgeon at Clinique Pasteur in Toulouse, France.
NIH and Clinical Excellence in the UK issued an Interventional Procedure Guidance Recommendation Approving Use of Aquablation® Therapy as an Alternative to Other Surgical Techniques for RX of BPH
10/1/18:“The NICE guidance is the first step in gaining full endorsement for widespread use of Aquablation in the UK,” said Nikolai Aljuri, PhD, PROCEPT BioRobotics co-founder, CEO and president.
PROCEPT BioRobotics’ Aquablation Meets Primary Endpoints in WATER II Study of 80 to 150 Milliliter Prostates
5/21/18: “On the heels of the WATER Study, the results of the WATER II Study confirmed Aquablation delivers predictable and reproducible results regardless of the size of the prostate,” said Dr. Desai.
PROCEPT BioRobotics, a Silicon Valley surgical robotics company developing novel and disruptive technologies to treat prostate disease, announced that the first commercial Aquablation® procedures have been completed in Germany. Additionally, the company has initiated the FRANCAIS WATER clinical trial, a necessary first step in gaining reimbursement for the company’s AquaBeam® System in France.
PROCEPT BioRobotics describes The WATER II study as a U.S. investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of Aquablation, delivered with the company's AquaBeam® System, in large prostates 80 to 150 milliliters (mL)...
12Page 1 of 2